Moderna
Moderna Reports $1.3B Loss and Cuts Back Production Amid Sales Dip
Moderna, once propelled to pharmaceutical prominence by its lucrative COVID-19 vaccine sales, now grapples with a decline in demand and ...
Moderna partners with CEPI to speed up vaccine development for future pandemics
Moderna is teaming up with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute to the 100 Days Mission, an ...
Pfizer Reduces Revenue Projection by $9 Billion Due to Declining COVID Sales, Prepares for Substantial Cost Reductions
As the COVID-19 pandemic transitions into an endemic phase, pharmaceutical companies have been bracing for a decline in demand for ...
Novavax partners with TV show star to promote COVID-19 vaccine choice and awareness
Novavax is gearing up for a robust marketing push to secure a share of the COVID-19 booster vaccine market this ...
CEPI funds BioNTech’s mRNA-based mpox vaccine trial with $90 million
BioNTech, the German biotech renowned for its groundbreaking mRNA COVID-19 vaccine, is embarking on clinical trials for an mRNA vaccine ...
Moderna axes four programs, including two former AstraZeneca collaborations
Moderna, following its recent phase 3 success with an mRNA flu vaccine, has made the decision to remove four clinical ...
Moderna’s mRNA flu vaccine shows phase 3 success, plans for combo shots by 2025
Moderna has achieved significant progress in its quest to develop an mRNA flu vaccine, with the updated mRNA-1010 version successfully ...
Moderna to cut down COVID booster production amid low demand: Reuters reports
While the FDA and the Centers for Disease Control and Prevention (CDC) have given their green light to updated COVID ...
Moderna Claims New COVID-19 Vaccine Can Protect Against Pirola Variant
Moderna is vigorously advocating for the expedited approval of its updated COVID-19 vaccine in preparation for the upcoming fall vaccination ...
Pfizer and BioNTech challenge Moderna’s mRNA vaccine patents in a bid to end monopoly
The legal battle between Moderna and its rivals Pfizer and BioNTech over the patents related to mRNA vaccine production is ...
Legal Engagements Amid Scientific Advancements: Alnylam’s Ongoing Interplay with Moderna
In the intricate choreography of the biopharmaceutical world, where innovation and intellectual property intertwine, a dramatic legal ballet unfolds. Alnylam, ...
A Symphony of Change: Moderna’s Second Serve at the US Open Celebrates Arthur Ashe’s Legacy
After paying homage to the iconic Billie Jean King in their previous year’s advertisement, this year’s rendition shines a spotlight ...
CARsgen and Moderna Join Forces to Explore Synergy Between CT041 and mRNA Cancer Vaccine
CARsgen Therapeutics has set the stage for an intriguing partnership with Moderna that’s bound to heat up the cancer therapy ...
Diversifying Strategies as Vaccine Demand Shifts: COVID-19 Vaccine Manufacturers Anticipate Fall Inoculation Season
Amidst a challenging environment of declining demand for COVID-19 vaccines, producers are eagerly awaiting the upcoming fall inoculation season as ...
GSK’s Arexvy Takes Lead in RSV Vaccine Race, Now Accessible at Leading US Pharmacies
In the competitive landscape of the respiratory syncytial virus (RSV) vaccine market, GlaxoSmithKline (GSK) stands out with its well-timed strides. ...
COVID-19 Vaccine Makers Prepare for Private-Market Launches Amid Evolving Variants
Following a decline in demand for COVID-19 vaccines, prominent biopharmaceutical companies are gearing up for private-market launches this upcoming fall. ...
Twitter and BioNTech under fire for evading COVID-19 vaccine questions
The regulatory organization overseeing the German communications sector has accused BioNTech of attempting to evade a public discussion regarding vaccine ...
Moderna finds promise in the private COVID vaccination market and the debut of RSV as sales plummet
Source – Fiercepharma As Moderna continues its operations beyond the pandemic, the biotech firm has increased its revenue projection for ...
GSK’s Arexvy and Moderna’s mRNA-1345 to lead the race for RSV prevention
The respiratory syncytial virus (RSV) is a common cause of respiratory infections, especially in infants and older adults. It can ...
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...
Moderna Files Two New Patent Lawsuits Against mRNA Competitors Pfizer and BioNTech
In the ongoing patent disputes surrounding COVID-19 vaccines, Moderna has expanded its legal battle against Pfizer and BioNTech by filing ...
Moderna Submits Global Regulatory Applications for its RSV Vaccine, mRNA-1345
Source – Moderna On July 5, 2023 Moderna, a biotech company at the forefront of mRNA vaccines, shared an update ...
Moderna to research and manufacture mRNA meds in China under $1B agreement
Despite ongoing political tensions between the United States and China, foreign investments in the pharmaceutical sector are progressing in China. ...
For its updated Covid-19 vaccine, Moderna submits a regulatory application to the European Medicines Agency
Source – Moderna On July 3, 2023 Moderna announced the submission of a regulatory application to the European Medicines Agency ...
Real Testimonials from Families Affected by CMV: Taking Action and Raising Awareness
Source – Moderna In 2011, Ayako Kamei, a Principal Scientist at Moderna Enzymatics, experienced the joy of welcoming her second ...
Moderna Application For FDA Approval Of Updated Covid-19 Vaccine
Source – Moderna On June 22, 2023, a regulatory application for Moderna’s updated COVID-19 mRNA vaccine (mRNA-1273.815), which contains spike ...
Comprehensive Guide to mRNA Vaccines: Advancements in COVID-19 Immunization
Introduction At our organization, we are dedicated to providing valuable information on the latest advancements in COVID-19 vaccines. In this ...
